Evidence map›Paper›PMID 38213538›Full record

ArticleExploration of targeted anti-tumor therapy2023

Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer.

Vignesh Sivaganesh, Bela Peethambaran

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. In Silico and in vitro Characterization ofIranian journal of pharmaceutical research : IJPR
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Vignesh SivaganeshDepartment of Biology, Saint Joseph's University, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0003-1775-6640
Bela PeethambaranDepartment of Biology, Saint Joseph's University, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0002-2719-3928
Philadelphia College of Osteopathic Medicine · USSaint Joseph's University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (AR Methods: The methods performed in this study include western blots, methyl thiazolyl tetrazolium (MTT) proliferation assays, phosphatidylserine apoptosis assays, apoptosis flow cytometry (Annexin V, caspase 3/7), migration scratch assays, Boyden chamber invasion assays, and cell cycle flow cytometry. Results: Strictinin was most lethal against PC3 [half-maximal drug inhibitory concentration (IC Conclusions: ROR1 is an emerging molecular target that can be utilized for treating prostate cancer. The data from this study establishes strictinin as a potential therapeutic agent that targets AR

Indexed as

castration-resistant prostate cancernatural therapyoncologyprostate cancerreceptor tyrosine kinasereceptor tyrosine kinase-like orphan receptor 1Small molecule inhibitorsstrictinin

Identifiers

PMID38213538
PMCPMC10784114
OpenAlexW4390029675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.